Dr Gregory Fontana, National Medical Director for Cardiovascular Research, at the Hospital Corporation of America, Nashville, Tennessee, (US), outlined promising preclinical data on Xeltis’ restorative aortic valves at the Heart Valve Society meeting in New York on April 13.
Dr Fontana reported that preliminary analysis of the aortic valves in animal model showed generally intact valves with minimal calcification and minimal thrombus formation 12 months after implant. Based on these results, Xeltis’ technology could potentially be used for various aortic valve designs, including transfemoral.
“The results suggest that heart valves based on ETR technology could allow durability improvement and expand their indication to a younger patient population,” Dr Fontana commented.
Xeltis’ restorative technology enables the patient’s body to form a new valve with own tissue, potentially reducing the risk of complications leading to further interventions. Clinical tests on the safety and feasibility of pulmonary valves based on Xeltis’ restorative technology are under way in several pediatric centers across the US. For more information: www.xplore2trial.com.
